Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008
Deleterious effects of ß-blockers on exercise capacity and hemodynamics in portopulmonary hypertension Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005
Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension Source: International Congress 2017 – PAH and CTEPH Year: 2017
Does sildenafil improves exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial Source: Annual Congress 2009 - Pulmonary vascular diseases Year: 2009
Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009
Hemodynamic correlates of exercise capacity in patients with pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 17s Year: 2005
Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 651s Year: 2006
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 372s Year: 2006
Effects of bosentan in patients with severe pulmonary hypertension and mild-to-moderate COPD Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009
Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005
Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Pulmonary hypertension and exercise capacity in patients with severe chronic obstructive pulmonary disease Source: Eur Respir J 2002; 20: Suppl. 38, 285s Year: 2002
The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Long-term safety and tolerance of ambrisentan in patients with pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 205s Year: 2005
Exercise tests and anxiety independently reflect physical quality of life in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016
Hemodynamic testing of acute vasoreagibility to sildenafil in patients with severe pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004
Sildenafil for patients with portopulmonary hypertension, candidates to hepatic transplant Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004